Antibacterial agent composition and antiviral agent composition comprising silicon-containing compound; antibacterializing method, cleaning/mouth rinsing method; method for fixing antibacterial agent and antiviral agent

ABSTRACT

Disclosed is an antibacterial agent composition which is highly safe and has excellent antibacterial abilities, by using a silicon-containing compound that is obtained by a specific manufacturing method. The antibacterial agent composition has a more stable antibacterial component, and is capable of imparting antibacterial abilities to teeth, while being also capable of cleaning an article or the mouth. Also disclosed are: an antiviral agent composition which is highly safe and has excellent virus deactivation abilities; an antibacterializing method, a cleaning/mouth rinsing method, each using the antibacterial agent composition or the antiviral agent composition; and a method for fixing an antibacterial agent or an antiviral agent. The antibacterial agent composition may contain a silicon-containing compound which is represented by general formula (1) and obtained by reacting a specific triethoxysilyl compound in an ethanol solvent.

TECHNICAL FIELD

The present invention generally relates to an antibacterial agentcomposition and an antiviral agent composition, containing asilicon-containing compound; antibacterializing method, cleaning/mouthrinsing method, using the antibacterial agent composition and a methodfor fixing an antibacterial agent using the antibacterial agentcomposition or a method for fixing an antiviral agent using theantiviral agent composition.

RELATED ART

As a concern over hygiene of daily-life environment increases, there isincreasingly a demand for higher hygiene and antibacterial standards forvarious articles, such as tableware, eyeglasses, sinks, kitchenfixtures, toilet, toilet fixtures, bathtubs, bath-room fixtures, washbowls, washroom fixtures, textile products and clothes. In addition, aspopulation of our society is aging, and largely to a global pandemic ofatypical influenza, there has been a strong demand for reducing therisks of infection or secondary infection significantly by simplyinactivating not only eumycetes, such as bacteria or molds, but alsopathogenic viruses, such as influenza virus or norovirus, and bytreating antibacterial and antiviral protection on articles in ourliving environment, such as towels or masks.

As such trends enhance more hygiene, antibacterial and antivirusintentions, there are increasing needs for such antibacterial agents andantiviral agents that can provide even higher sterilization andpathogenic virus inactivation abilities than those of conventionalantibacterial and antiviral agents. For example, Patent Documents 1-3disclose silicon-containing compounds that can provide an antibacterialability, describing different forms of compositions employing suchcompounds.

On the other hand, focusing in particular on dental materials, moredenture cleaners have been used by more denture users and denturecleansers of different compositions have been used. As such, there is aneed for an antibacterial agent composition that combines the ability toallow a denture to be used again after a brief cleaning process with thecleaning ability such that the antibacterial ability lasts for a longperiod of time.

For example, when classifying the conventional antibacterial agentcompositions capable of offering such cleaning abilities by componentsystem, they can be classified as one comprising a major component ofeither a peroxide, hypochlorous acid, enzyme, acid, crude drug,silver-based inorganic antibacterial agent or disinfectant,alternatively as another combining two or more components thereof. Thespecific composition varies in the antibacterial agent compositionsbelonging to the same component system. This is because if both cleaningand sterilization abilities are required for an antibacterial agentcomposition, such an antibacterial agent composition is often composedof a combination of compositions exerting respective effects.

In order to fulfill such requirements, for example, Patent Document 4discloses a detergent composition with high cleaning and sterilizationabilities, aimed at improving the antibacterial ability, the cleaningability and the persistence for a cleaned article being cleaned, andhaving both antibacterial and cleaning abilities that can preventdenture plaques from re-forming on a denture surface while the dentureis being fixed in the oral cavity in dental materials, such as implants,crowns, bridges, orthodontic brackets or dental wires, in particular,dentures; and a denture cleanser composition that can provide a denturewith the antibacterial ability, in particular, without giving a dentureuser special burden or uncomfortable feeling.

RELATED ART DOCUMENT Patent Document

-   Patent Document 1: JP-A-2007-502328-   Patent Document 2: JP-A-H6-505036-   Patent Document 3: JP-A-2006-213709-   Patent Document 4: JP-A-2007-146134

DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention

However, as disclosed in Patent Documents 1-3, if a silicon-containingcompound formed by a so-called methoxy body, such as, e.g.,octadecyldimethyl(3-trimethoxysilylpropyl)ammonium chloride, iscontained in a composition, many problems remain to be resolved for thecomposition itself since involvement of highly toxic methanol cannot beavoided during production, transportation or use. Besides, it is stilluncertain whether sufficient effects can be exerted to inactivatepathogenic viruses, in particular, influenza viruses and others.

On the other hand, a silicon-containing compound of antibacterialcomponents comprised in the detergent composition as disclosed in PatentDocument 4 above provides such a stability in a solution that depends onthe solvent to be dissolved and the type of surfactant to mix.Accordingly, in some cases, this can generate cloudy gelation, therebydecreasing the antibacterial ability imparting performance of thedetergent composition. Moreover, to meet the increasing demands forfurther enhanced hygiene and antibacterial intentions, there is still aneed for an antibacterial agent composition that has further improvedantibacterial abilities and more persistent antibacterial abilities.

In addition, if such an antibacterial agent composition can impartdisinfection/sterilization while cleaning and antibacterial abilities,it is effective for realizing more hygienic environment and preventinginfection of pathogens. Patent Document 4, however, only disclosescleaning and antibacterialization of the article of the detergentcomposition, but does not consider whether or not the detergentcomposition can impart disinfection/sterilization while cleaning andantibacterial abilities.

Moreover, if such an antibacterial detergent can achieveantibacterialization of hydroxyapatite which is a principal component ofthe teeth in addition to cleaning and antibacterialization of thedenture, it is very effective for treatment/prevention of dental caries,periodontal diseases and other dental infectious diseases and aspirationpneumonia when used as a dentifrice/mouthwash. Patent Document 4,however, does not consider whether or not the detergent compositionallows for antibacterialization of teeth or a principal componentthereof, hydroxyapatite.

Additionally, if such a high performance antibacterial agent compositionand antiviral agent composition can be firmly adhered to a surface ofthe article, it is also predicted to result in more valuablecomposition.

Therefore, the present invention has been made to solve theabove-discussed problems. An object of the present invention is toprovide an antibacterial agent composition which is highly safe and hasexcellent antibacterial abilities, by using a silicon-containingcompound that is obtained by a specific manufacturing method, theantibacterial agent composition having a more stable antibacterialcomponent, being capable of imparting antibacterial abilities to teeth,while being also capable of cleaning an article and the mouth, as wellas an antiviral agent composition that ensures both high safety andexcellent virus inactivation abilities, and to provide anantibacterializing method and a cleaning/mouth rinsing method, as wellas a method for fixing an antibacterial agent and an antiviral agent,each using these compositions.

Means for Solving the Problem

As a result of intensive studies to address the above-mentionedproblems, the inventors found an antibacterial agent composition thatcontains a silicon-containing compound obtained as an antibacterialcomponent by a specific manufacturing method, and an antiviral agentcomposition that contains a particular silicon-containing compound.Based on this, the present invention is completed.

That is, an antibacterial agent composition of the present inventioncomprises the composition comprising silicon-containing compoundobtained from general formula (a):

X—(CH₂)₃—Si—(OCH₂CH₃)₃  (a),

wherein X represents halogen ion or organic carbonyloxy ion (organiccarboxylate ion), which represents triethoxysilyl compound reacted inethanol solvent to prepare by general formula (1):

wherein R¹ represents an alkyl group having from 12 to 24 carbon atoms;R² and R³ represent lower alkyl groups, respectively, having from 1 to 6carbon atoms, which carbon atoms may be the same or different from eachother; and X represents a halogen ion or an organic carbonyloxy ion(organic carboxylate ion).

It is desirable that the silicon-containing compound represented by thegeneral formula (1) is octadecyldimethyl(3-triethoxysilylpropyl)ammoniumchloride.

The above-mentioned antibacterial agent composition may further containethanol, water and even an amphoteric surfactant and/or a cationicsurfactant.

An antibacterializing method of the present invention mayantibacterialize a surface of an article with the above-describedantibacterial agent composition.

A cleaning/mouth rinsing method of the present invention may performcleaning and mouth rinsing by using the antibacterial agent composition.

An antiviral agent composition of the present invention may comprise asilicon-containing compound represented by general formula (1):

wherein R¹ represents an alkyl group having from 12 to 24 carbon atoms;R² and R³ represent lower alkyl groups, respectively, having from 1 to 6carbon atoms, which carbon atoms may be the same or different from eachother; and X represents a halogen ion or an organic carbonyloxy ion(organic carboxylate ion).

It is desirable that the silicon-containing compound presented by thegeneral formula (1) is octadecyldimethyl(3-triethoxysilylpropyl)ammoniumchloride.

The above-mentioned antiviral agent composition may further containethanol, water and even an amphoteric surfactant and/or a cationicsurfactant.

It is desirable that the antiviral agent composition has the ability toinactivate at least one type of virus selected from the group consistingof type A influenza virus (human, avian, swine (atypical)), type Binfluenza virus, parainfluenza virus and norovirus.

A method for fixing an antibacterial agent of the present invention maycomprise: by means of a article having an oxygen-containing functionalgroup on its surface, applying or spraying the above-describedantibacterial agent composition onto the surface of the article, orimmersing the article in the antibacterial agent composition.

A method for fixing an antiviral agent of the present invention maycomprise using a article having an oxygen-containing functional group onits surface and applying or spraying the antiviral agent compositiononto a surface of the article; or immersing the article in theantibacterial agent composition.

EFFECT OF THE INVENTION

With the antibacterial agent composition and the antiviral agentcomposition of the present invention, since they contain asilicon-containing compound formed by a so-called ethoxy body and havingan ethoxy group obtained by a specific manufacturing method, highlytoxic methanol is not involved at all during production, transportationor use, and extremely high safety may be ensured as compared withconventional agents containing a silicon-containing compound formed by amethoxy body, while providing excellent antibacterial and antivirusabilities.

In general, bacteria and viruses can take only one or two hours toproliferate until approximately doubled in number. Accordingly, if thenumber of bacteria and viruses can be reduced 1000 times smaller, then aperiod of time of tens of hours will be left before they can proliferateto the above-mentioned number. This should provide considerableantibacterial and antivirus abilities. Here, the antibacterial andantivirus abilities achieved by the antibacterial agent composition andthe antiviral agent composition of the present invention are such thatthe number of survival bacteria or the amount of survival viruses can bereduced by several orders of magnitude to substantially zero, ascompared with applying conventional agents containing asilicon-containing compound formed by a methoxy body. This makes anextraordinary epoch-making effect and proves very valuable. Such anantiviral ability is very effective against, in particular, type Ainfluenza virus (human, avian, swine (atypical)), type B influenzavirus, parainfluenza virus or norovirus.

In addition, a combination of a surfactant specific to theabove-described antibacterial agent composition and antiviral agentcomposition with a particular solvent may ensure stabilization of theantibacterial component for a long period of time, achieve strongerantibacterial abilities and the persistence than would be providedconventionally, and further disinfection/sterilization of a article aswell as effective antibacterialization of teeth by mouth rinsing,thereby realizing simple and effective antibacterialization of the teethor hydroxyapatite.

Moreover, according to the methods for fixing an antibacterial agent andfixing an antiviral agent of the present invention, it is possible tomake an antibacterial agent and an antiviral agent adhered to a surfaceof an article effectively. This allows these agents to fully exploittheir own antibacterial and antiviral abilities under high safetyconditions.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph depicting the result of a test for comparingantibacterial abilities between EtAC and Si-QAC in Example 3, where thevertical axis represents absorbance;

FIG. 2 is a graph depicting the result of an antibacterial ability testin an EtAC aqueous solution in Example 6, where the vertical axisrepresents the number of bacteria detected (logarithmic value);

FIG. 3 is a graph depicting the result of a virus infection inactivatingability test against influenza virus in Example 9, where the verticalaxis represents the concentration of EtAC (%) while the horizontal axisrepresents the amount of survival influenza viruses (%);

FIG. 4 is a graph depicting the result of a virus infection inactivatingability test against atypical (swine) influenza viruses (type H1N1) inExample 9, where the vertical axis represents the amount of survivalinfluenza viruses (virus survival rate: %); and

FIG. 5 is a graph depicting the result of an anti-influenza virus effecttest of an EtAC-treated towel and an EtAC-treated glass vial in Example10, where the vertical axis represents 50% infectious dose (tissueculture infectious dose [TCID50]).

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention will now be described further in detail below. Itshould be noted that the term “antibacterial” as used herein meanssterilization or impairment of bacteria and eumycetes, or otherwiseprevention of their proliferation; and “antiviral” refers toinactivation of pathogenic viruses.

An antibacterial agent composition of the present invention comprisesthe composition comprising silicon-containing compound obtained fromgeneral formula (a):

X—(CH₂)₃—Si—(OCH₂CH₃)₃  (a),

wherein X represents halogen ion or organic carbonyloxy ion (organiccarboxylate ion), which represents triethoxysilyl compound reacted inethanol solvent to obtain an antibacterial agent composition of thepresent invention represented by general formula (1):

wherein R¹ represents an alkyl group having from 12 to 24 carbon atoms;R² and R³ represent lower alkyl groups, respectively, having from 1 to 6carbon atoms, which carbon atoms may be the same or different from eachother; and X represents a halogen ion or an organic carbonyloxy ion(organic carboxylate ion).

In formulas (a) and (1), X may exemplify a halogen ion, such as chlorideion or bromine ion, and an organic carbonyloxy ion (organic carboxylateion), such as methylcarbonyloxy ion (acetate ion), ethylcarbonyloxy ion(propionate ion) or phenylcarbonyloxy ion (benzoate ion).

The alkyl group having 12-24 carbon atoms of R1 in the formula (1) mayexemplify a dodecyl group, tridecyl group, tetradecyl group, pentadecylgroup, hexadecyl group, heptadecyl group, octadecyl group, nonadecylgroup, eicosyl group, uneicosyl group, doeicosyl group, trieicosylgroup, tetraeicosyl group and so on.

In the formula (1), the lower alkyl groups of 1-6 carbon atoms of R2 andR3 that may be the same or different, may include, for example, a methylgroup, ethyl group, propyl group, isopropyl group, butyl group, pentylgroup, hexyl group and cyclohexyl group.

That is, the silicon-containing compound represented by the generalformula (1) that is contained in the antibacterial agent composition ofthe present invention is a particular silicon-containing compoundobtained by reacting a particular triethoxysilyl compound represented bythe general formula (a) in an ethanol solvent. Such a silicon-containingcompound represents a so-called ethoxy body of a silicon-containingcompound that is bound three ethoxy groups to a silicon atom.

As is the case with conventional silicon-containing compounds, anyso-called methoxy body of silicon-containing compound with bindingbetween a methoxy group to a silicon atom and requires methanol duringproduction, and so methanol can be generated by a side reaction, such ashydrolysis, even after production. However, it has been pointed out thatmethanol is more likely toxic by oral administration, could cause strongeye irritation and have adverse effects on fertility or embryos, causedisorders of central nervous system, visual organ, systemic toxicity orstimulation to respiratory organs, and could also induce sleepiness ordizziness, thereby causing disorders of central nervous system or visualorgan due to a long-term or repetitive exposure. Thus, conventionally,the presence of such methanol has endangered the safety of the resultantsilicon-containing compound itself, as well as the safety ofantibacterial agent compositions containing the compound.

In contrast, according to the present invention, an ethanol solvent isutilized during production of the above-mentioned silicon-containingcompound, whereas a highly toxic solvent, such as methanol, is not usedat all and no methanol is generated from such a silicon-containingcompound formed by an ethoxy body whatsoever by a side reaction, such ashydrolysis. Accordingly, the resultant antibacterial agent compositionis extremely safe. Moreover, there is no concern that asilicon-containing compound, such as a methoxy body, is obtained as aby-product when a particular triethoxysilyl compound represented by thegeneral formula (a) is reacted in an ethanol solvent.

Specific examples of the silicon-containing compound represented by thegeneral formula (1) includeoctadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride,tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride,pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,pentadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,pentadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride,hexadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,hexadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride,octadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,octadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, and soon. Among these, octadecyldimethyl(3-triethoxysilylpropyl)ammoniumchloride is preferable for the least biological toxicity, the leastenvironmental load during use and the least environmental load ofwastewater.

To produce the above-described silicon-containing compound, a particulartriethoxysilyl compound represented by the general formula (a) isreacted in an ethanol solvent. By reacting these in an ethanol solvent,generation of by-products such as methoxy bodies can be effectivelysuppressed and the safety of the resultant silicon-containing compoundcan be significantly improved. Specifically, a particular triethoxysilylcompound represented by the general formula (a) is reacted in an ethanolsolvent with an amine represented by general formula (b):

wherein R¹ represents an alkyl group having from 12 to 24 carbon atoms;R² and R³ represent lower alkyl groups, respectively, having from 1 to 6carbon atoms, which carbon atoms may be the same or different from eachother.

More specifically, for example, if octadecyldimethyl(3-triethoxysilylpropyl) ammonium chloride is produced,triethoxysilylpropyl chloride, as a triethoxysilyl compound representedby the general formula (a), N,N-dimethyloctadecylamine, as an aminerepresented by the general formula (b), and ethanol are fed into areactor, heated typically to 100-180° C., preferably to 120-150° C., andthen reacted typically for 10-60 hours, preferably for 20-40 hours. Itis desirable that the mole ratio of triethoxysilyl compound to amine forreaction is normally 1.5:0.8-1:1. It should be noted that theconcentrations of the triethoxysilyl compound and amine in ethanol maybe changed as necessary without limitation.

Although not limited to a particular value as long as the antibacterialeffect and the persistence are ensured, the content of theabove-described silicon-containing compound in the antibacterial agentcomposition of the present invention is normally 0.6 ppm or more,preferably 20 ppm or more, more preferably 0.006-24% by weight, and mostpreferably 0.06-6% by weight. The silicon-containing compound ispreferably within the aforementioned ranges for obtaining a sufficientantibacterial effect and the persistence.

The antibacterial agent composition of the present invention may furthercontain ethanol. Without limitation, the content of ethanol ispreferably 50-85% by volume with respect to the fixing on antibacterialeffect. In addition, the content of ethanol is preferably 35-85% byvolume with respect to fixing such an antibacterial agent composition toa article. The antibacterial agent composition may further containwater. That is, the antibacterial agent composition may contain, as asolvent, either water, ethanol or an ethanol aqueous solution (suchsolvent will be referred to hereinafter as “water and/or ethanol”). Whenany of the above is used as a solvent, as long as the content of theabove-described silicon-containing compound falls within theabove-mentioned range, each of these solvents has an extremely lowtoxicity in comparison to methanol, and may significantly improve thesafety of the resultant antibacterial agent composition. This mayprovide an agent that combines high safety with excellent antibacterialeffect.

Moreover, such an antibacterial agent composition may contain, dependingon the usage, at least one type of amphoteric surfactant or at least onetype of cationic surfactant or both amphoteric and cationic surfactants.Among these, it is desirable to contain the amphoteric surfactant. Ifthese surfactants are contained, it becomes easier to make thesilicon-containing compound stable in an agent, thereby preventingcloudiness and gelation of the solution.

The above-described amphoteric surfactant is preferably of at least onetype selected from the group consisting of betaine-based and amineoxide-based surfactants. Among these, an amine oxide-based amphotericsurfactant is preferable in favor of further stabilization ofantibacterial component.

Examples of the betaine-based amphoteric surfactant include coco fattyacid amidepropyl carboxybetaine, betaine lauryldimethyl aminoacetate,imidazolium betaine and so on. Among these, coco fatty acid amidepropylcarboxybetaine and betaine lauryldimethyl aminoacetate are preferable infavor of stability of the silicon-containing compound which is anantibacterial component in water and/or ethanol.

Examples of the amine oxide-based amphoteric surfactant include lauryldimethyl amine oxide, lauroylamidopropyl dimethylamine oxide and so on.Among these, lauryl dimethyl amine oxide is preferable in favor oflong-term stability of the silicon-containing compound which is anantibacterial component in water and/or ethanol.

Examples of the cationic surfactant include: a cationic surfactant(except the silicon-containing compound), such as cetylpyridiniumchloride; N-cocoyl-alginine ethyl ester pyridone carboxylate; and so onrepresented by general formula (2):

wherein R¹¹ represents a hydrocarbon group having 6 or more carbonatoms; R¹², R¹³ and R¹⁴ represent lower hydrocarbon groups,respectively, which hydrocarbon groups may be the same or different fromeach other; Y represents a halogen ion or an organic carbonyloxy ion.

In the cationic surfactant presented by the general formula (2), it ispreferred that R¹¹ represents an alkyl group having 10 to 25 carbonatoms, R12, R¹³ and R¹⁴ are lower alkyl groups having 1 to 6 carbonatoms that may be the same or different, and Y represents a halogen ionor an organic carbonyloxy ion (organic carboxylate ion).

Examples of the hydrocarbon group R11 having 6 or more carbon atoms ofthe cationic surfactant represented by the general formula (2) mayinclude hexyl group, heptyl group, octyl group, nonyl group, decylgroup, decyl group, dodecyl group, tridecyl group, tetradecyl group,pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group,nonadecyl group, eicosyl group, uneicosyl group, doeicosyl group,trieicosyl group, tetraeicosyl group, pentaeicosyl group and so on.

Examples of R12, R13 and R14 of the cationic surfactant represented bythe general formula (2) may include methyl group, ethyl group, propylgroup, isopropyl group, butyl group, pentyl group, hexyl group,cyclohexyl group, phenyl group, tolyl group and so on.

Specific examples of the cationic surfactant represented by the generalformula (2) may include the following compounds: decyltrimethylammoniumchloride, decyltriethylammonium acetate, dodecyltrimethylammoniumacetate, dodecyltriisopropylammonium bromide, tridecyltriethylammoniumbromide, tetradecyltrimethylammonium chloride,tetradecyltriethylammonium chloride, tetradecyltri-n-propylammoniumchloride, pentadecyltrimethylammonium chloride,pentadecyltriethylammonium chloride, pentadecyltri-n-propylammoniumchloride, hexadecyltrimethylammonium chloride, hexadecyltriethylammoniumchloride, hexadecyltri-n-propylammonium chloride,octadecyltrimethylammonium chloride, octadecyltriethylammonium chloride,octadecyltri-n-propylammonium chloride and so on. Among these,hexadecyltrimethylammonium is most preferable.

Among the above-listed cationic surfactants, hexadecyltrimethylammoniumand cetylpyridinium chloride are particularly preferable since they mayfurther improve the antibacterial ability and stability.

In addition, particularly, when a low content of the silicon-containingcompound is used under a short term treatment condition, among theabove-listed amphoteric and cationic surfactants, lauryl dimethyl amineoxide which is a amphoteric surfactant is particularly preferable withrespect to better antibacterial abilities. It is estimated that thereason why a remarkable antibacterial ability is obtained even under asevere condition is that an intermediate is produced by the reaction oflauryl dimethyl amine oxide with the silicon-containing compound, andsuch an intermediate contributes to enhancement of reactivity as anantibacterial component.

The content of the amphoteric surfactant is normally 0.007-20 w/v %,preferably 0.05-10 w/v %. The amphoteric surfactant is preferably withinthe aforementioned ranges in order to obtain a sufficient antibacterialeffect and the persistence. Particularly, when the silicon-containingcompound in the above-described antibacterial agent composition is fixedto an article, such as a dental material, a textile product including atowel or clothes, the silicon-containing compound in the antibacterialagent composition may demonstrate its effect to a sufficient extent ifthe content of the silicon-containing compound is normally not less than0.03% by weight, preferably not less than 0.06% by weight. It isdesirable, without limitation, that the upper limit is equal to or lessthan 0.6% by weight, in terms of cost. Further, if a cationic surfactantis contained, the content of the cationic surfactant is preferably0.01-5 w/v %, and preferably 0.05-1 w/v % with respect to improvement ofthe stability and antibacterial ability of the silicon-containingcompound.

The antibacterial agent composition may also be used as a detergentcomposition for exerting a detergent effect, in particular, ifcontaining a amphoteric surfactant. Such a detergent composition mayremain stable for a long period of time without cloudy gelation of thesilicon-containing compound which is an antibacterial agent compositionthereof, offer stronger antibacterial abilities than the conventionaldetergent compositions, and further enable antibacterialization ofteeth. Accordingly, it is useful as a dentifrice/mouthwash fortreatment/prevention of dental caries, periodontal diseases and otherdental infectious diseases, aspiration pneumonia and so on. In addition,such a detergent composition may further contain at least one type ofcationic surfactant. The antibacterial ability, antibacterialpersistence and stability of the detergent composition of the presentinvention may be further improved by addition of the cationicsurfactant.

The antibacterial agent composition is also useful, especially whencontaining a cationic surfactant, as a composition for disinfection,cleaning, mouth rinsing, sterilization and antibacterialization fordisinfecting, cleaning, sterilizing and antibacterializing composition.Such a composition for disinfection, cleaning, mouth rinsing,sterilization and antibacterialization may be used as adentifrice/mouthwash for treatment/prevention of dental caries,periodontal diseases and other dental infectious diseases, aspirationpneumonia and so on since it allows for antibacterialization of teeth asis the case with the antibacterial agent composition of the presentinvention.

The content of the silicon-containing compound in these detergentcomposition and composition for disinfection, cleaning, mouth rinsing,sterilization and antibacterialization is normally 0.6 ppm or more,preferably 20 ppm or more, more preferably from 0.006 to 24% by weight,and most preferably from 0.06 to 6% by weight, as is the case with theantibacterial agent composition of the present invention as mentionedearlier. The silicon-containing compound is preferably within theaforementioned ranges for obtaining a sufficient antibacterial abilityand the persistence. Particularly, when the silicon-containing compoundin the above-described composition for sterilization, cleaning, mouthcleaning, sterilization and antibacterialization is fixed to an article,such as a dental material, a textile product including a towel orclothes, the silicon-containing compound in that composition maysufficiently demonstrate its effect if the content of thesilicon-containing compound is normally not less than 0.03% by weight,preferably not less than 0.06% by weight. It is desirable, withoutlimitation, that the upper limit is equal to or less than 0.6% byweight, in terms of cost.

The content of cationic surfactant in the above-described compositionfor disinfecting, cleaning, sterilization and antibacterialization ispreferably from 0.01 to 5 w/v %, and preferably from 0.5 to 3 w/v %,with respect to improving the stability and antibacterial ability of theabove-described silicon-containing compound in water and/or ethanol.

The antibacterializing method of the present invention may exertdisinfection, cleaning, sterilization and antibacterialization effects,and characterized bydisinfection/cleaning/sterilization/antibacterialization of a surface ofthe article with the antibacterial agent composition (detergentcomposition) of the present invention. Specifically, thedisinfection/cleaning/sterilization/antibacterialization of the articlewith the antibacterial agent composition may be performed by immersingthe article in the antibacterial agent composition; applying or sprayingthe above-described antibacterial agent composition onto a surface ofthe article; rinsing a surface of the article several times with theantibacterial agent composition; or wiping a surface of the article witha cloth or the like soaked with the antibacterial agent composition.Accordingly, any methods can be used without limitation that allow forcontact between the article and the antibacterial agent composition fora predetermined period of time. In addition, a predetermined period oftime can be the time to sufficiently react the antibacterial componentcomprising the above antibacterial agent composition with the surface ofan article, and may be selected appropriately. It should be noted thatfollowing the disinfection/cleaning/sterilization/antibacterializationwith the antibacterial agent composition, the antibacterial agentcomposition may be eliminated from the surface of an article by washingwith water, if necessary.

Articles to be disinfected/cleaned/sterilized/antibacterialization bythe antibacterializing method of the present invention may includevarious articles, including dental materials such as implants, crowns,bridges, orthodontic brackets or dental wires, and other articles suchas tableware, glasses, sinks, kitchen goods, toilet bowls, toilet goods,bathtubs, bath goods, lavatory bowls, lavatory goods, textile productsincluding towels or clothes, and so on.

In addition, the cleaning/mouth rinsing method of the present inventionmay sterilize and antibacterialize the article, wherein the method ischaracterized bydisinfection/cleaning/sterilization/antibacterialization with theantibacterial agent composition of the present invention (thecomposition for disinfection, cleaning, mouth rinsing, sterilization andantibacterialization). Specifically, this may be performed by immersingthe article in the antibacterial agent composition, wiping a surface ofthe article with a cloth or the like soaked with the antibacterial agentcomposition, or applying or spraying the antibacterial agent compositiononto the article. Accordingly, any method can be used without limitationthat allow for contact between the article and the antibacterial agentcomposition for a predetermined period of time. In addition, apredetermined period of time can be the time to sufficiently react theantibacterial component comprising the above antibacterial agentcomposition with the surface of an article, and may be selectedappropriately. Alternatively, the antibacterial agent composition of thepresent invention (the composition for disinfection/cleaning/mouthrinsing/sterilization/antibacterialization) may also be used for mouthrinsing. Specifically, mouth rinsing with the antibacterial agentcomposition may be performed, e.g., by rinsing the oral cavity throughgargling with the antibacterial agent composition for mouth rinsing.

According to this cleaning/mouth rinsing method, the above-describedantibacterial agent composition offering an excellent antibacterialability imparting performance and a persistent antibacterial propertymay be used to clean/disinfect/sterilize the mouth effectively andimpart excellent antibacterial abilities and persistent antibacterialproperties to teeth.

In the method for stabilizing said silicon-containing compound in waterand/or ethanol, moreover, a method for stabilizing thesilicon-containing compound of the present invention represented by thegeneral formula (1) in water and/or ethanol may also be adopted based onthe use of at least one type of amine oxide-based amphoteric surfactant.The silicon-containing compound represented by the general formula (1)may coexist with an amine oxide-based amphoteric surfactant in waterand/or ethanol, which results in said silicon-containing compound beingstabilized in water and/or ethanol over a long period of time. As aresult, an antibacterial agent composition may be produced that preventscloudiness and gelation of the solution and offers excellentantibacterial abilities and persistent antibacterial properties.

In the method for stabilizing the silicon-containing compound of thepresent invention represented by the general formula (1) in water and/orethanol, at least one type of amine oxide-based amphoteric surfactantmay also be used together with at least one type of cationic surfactant,in which case similar results can be obtained.

In the method for stabilizing the silicon-containing compound of thepresent invention represented by the general formula (1) in water and/orethanol, the silicon-containing compound represented by the generalformula (1), the amine oxide-based amphoteric surfactant and thecationic surfactant are the same as those contained in the antibacterialagent composition of the present invention. In addition, it is preferredthat the contents of the silicon-containing compound and the amineoxide-based amphoteric surfactant are within the same range as thosecontained in the antibacterial agent composition of the presentinvention for the silicon-containing compound to be stabilized in waterand/or ethanol and the resultant solution to exert an antibacterialeffect and the persistence in a sufficient manner. It should be notedthat if a cationic surfactant is used, the content of the cationicsurfactant is preferably within the same range as that contained in theantibacterial agent composition with respect to improve stability andantibacterial ability of the silicon-containing compound.

In addition, the method for stabilizing the silicon-containing compoundof the present invention represented by the general formula (1) in waterand/or ethanol uses at least one type of cationic surfactant in a methodfor stabilizing the silicon-containing compound in water and/or ethanol.The silicon-containing compound represented by the general formula (1)may coexist with the cationic surfactant in water and/or ethanol, whichresults in said silicon-containing compound being stabilized in waterand/or ethanol over a long period of time. As a result, an antibacterialagent composition may be produced that prevents cloudiness and gelationof the solution, offers excellent antibacterial abilities and persistentantibacterial properties, and achieves disinfection and sterilization.

In the method for stabilizing the silicon-containing compound of thepresent invention represented by the general formula (1) in water and/orethanol, the silicon-containing compound represented by the generalformula (1) and the cationic surfactant are the same as those containedin the antibacterial agent composition of the present invention. Inaddition, it is preferred that the contents of the silicon-containingcompound and the cationic surfactant are within the same range as thosecontained in the antibacterial agent composition of the presentinvention for the silicon-containing compound to be stabilized in waterand/or ethanol and the resultant solution to exert an antibacterialeffect and the persistence in a sufficient manner.

In addition, the antibacterial agent composition of the presentinvention may also antibacterialize teeth or hydroxyapatite. Theantibacterial agent composition of the present invention may simplyprovide teeth or hydroxyapatite which is a principal component of theteeth with an excellent antibacterial ability such that the abilitylasts for a long period of time. It is preferred thatantibacterialization is performed with the antibacterial agentcomposition of the present invention since an excellent antibacterialability can last for a longer period of time.

The antibacterialization of the teeth or hydroxyapatite withantibacterial agent composition of the present invention may beperformed by, specifically, immersing the teeth or hydroxyapatite in theantibacterial agent composition of the present invention, applying orspraying the antibacterial agent composition of the present inventiononto a surface of the teeth or hydroxyapatite, or wiping the surface ofthe teeth or hydroxyapatite with a cloth or the like soaked with theantibacterial agent composition of the present invention. Accordingly,any methods can be used without limitation that allows contact betweenthe teeth or hydroxyapatite and the antibacterial agent composition fora predetermined period of time. In addition, a predetermined period oftime can be the time to sufficiently react the antibacterial componentcomprising the above antibacterial agent composition onto the surface ofan article, and may be selected appropriately.

An antiviral agent composition of the present invention may comprise asilicon-containing compound represented by the general formula (1):

wherein R¹ represents an alkyl group having from 12 to 24 carbon atoms;R² and R³ represent lower alkyl groups, respectively, having from 1 to 6carbon atoms, which carbon atoms may be the same or different from eachother; and X represents a halogen ion or an organic carbonyloxy ion(organic carboxylate ion). In the general formula (1), R¹, R², R³ and Xare defined to have the same meaning as those of the silicon-containingcompound in the above-mentioned antibacterial agent composition of thepresent invention. No highly toxic methanol is produced by a sidereaction, such as hydrolysis, from such a silicon-containing compoundformed by an ethoxy body, which compound is thus very safe. If such acompound is contained, such an antiviral agent composition that has bothhigh safety and excellent antiviral ability can be achieved.

Specific examples of the silicon-containing compound represented by thegeneral formula (1) includeoctadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride,tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride,pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,pentadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,pentadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride,hexadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,hexadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride,octadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride,octadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride and so on.Among these, octadecyldimethyl(3-triethoxysilylpropyl)ammonium chlorideis preferable for the least biological toxicity, the least environmentalload during use and the least environmental load of wastewater.

Preferably, the silicon-containing compound represented by the generalformula (1) is obtained by reacting the triethoxysilyl compoundrepresented by the general formula (a) in an ethanol solvent:

X—(CH₂)₃—Si—₃)₃  (a),

wherein X represents a halogen ion or an organic carbonyloxy ion(organic carboxylate ion). Such a triethoxysilyl compound is the same asthe triethoxysilyl compound in the antibacterial agent composition ofthe present invention, and is produced by the same method as thesilicon-containing compound in the antibacterial agent composition ofthe present invention. That is, such a reaction eliminates the need forusing a highly toxic solvent, such as methanol, even when producing theabove-described silicon-containing compound, which may result in a saferantiviral agent composition.

In addition, although not limited to a particular value as long as theantiviral effect and the persistence are ensured, the content of theabove-described silicon-containing compound in the antiviral agentcomposition of the present invention is normally 0.6 ppm or more,preferably 20 ppm or more, more preferably from 0.006 to 24% by weight,and most preferably from 0.06 to 6% by weight. The silicon-containingcompound is preferably within the aforementioned ranges for obtaining asufficient antiviral effect and the persistence.

The antiviral agent composition of the present invention may furthercontain ethanol. Without limitation, the content of ethanol ispreferably 50-85% by volume with respect to fixing primarily onantiviral effect. In addition, the content of ethanol is preferably35-85% by volume in favor of fixing such an antiviral agent compositionto a substance. The antiviral agent composition may further containwater. That is, the antiviral agent composition may contain, as asolvent, any of water, ethanol or an ethanol aqueous solution (waterand/or ethanol). Any of these solvents has an extremely low toxicity incomparison to methanol and may significantly improve the safety of theresultant antiviral agent composition. This may provide an agent thatcombines high safety with excellent antiviral effect. In this way, byonly comprising the silicon-containing compound, and, if necessary,water and/or ethanol, pathogenic viruses may be inactivated in a simpleand effective manner and infection spread of pathogenic viruses may beprevented, thereby enhancing the hygiene environment.

Examples of viruses that can be inactivated by the antiviral agentcomposition include type A influenza virus (humans, avian, swine(atypical)), type B influenza virus, parainfluenza virus, (type A-E)hepatitis virus, measles virus, herpes virus, mumps virus, envelopedvirus, such as rabies virus or influenza virus, norovirus, HIV virus andso on. Among these, influenza virus and norovirus are preferable, and inparticular, this antiviral agent composition proves highly valuable, inparticular, with respect to the fact that it exerts an excellentinactivation ability against type A influenza virus (swine (atypical))(atypical (swine) influenza virus (type H1N1)).

Moreover, such an antiviral agent composition may contain, depending onthe usage, at least one type of amphoteric surfactant or at least onetype of cationic surfactant or both amphoteric and cationic surfactants.Above all, it is desirable to contain the amphoteric surfactant. Ifthese surfactants are contained, it becomes easier to make thesilicon-containing compound stable in an agent, thereby preventingcloudiness and gelation of the solution. It should be noted that theavailable types and contents of the amphoteric surfactant and thecationic surfactant are the same as those described in relation to theabove antibacterial agent composition of the present invention.

The inactivation of viruses with the antiviral agent composition of thepresent invention may be specifically performed by immersing the articleto which viruses may be attached in the antiviral agent composition;applying or spraying the antiviral agent composition onto the article;or wiping a surface of the article with a cloth or the like soaked withthe antiviral agent composition. Accordingly, any methods can be usedwithout limitation that allow for contact between the article and theantiviral agent composition for a predetermined period of time. Inaddition, a predetermined period of time can be the time to sufficientlyreact the antibacterial component comprising the above antibacterialagent composition onto a surface of the article, and may be selectedappropriately.

The method for fixing the antibacterial agent of the present inventioncharacterized by applying or spraying the antibacterial agentcomposition onto a surface of the article; or immersing the article inthe antibacterial agent composition, by utilizing the substancecomprising oxygen functional group on its surface. Similarly, the methodfor fixing the antiviral agent of the present invention characterized byapplying or spraying the antibacterial agent composition onto a surfaceof the article; or immersing the article in the antibacterial agentcomposition, by utilizing an article comprising oxygen functional groupon its surface. That is, these methods for fixing the antibacterialagent and for fixing the antiviral agent correspond to a method forapplying or spraying the antibacterial agent composition or theantiviral agent composition onto a surface, or a method for immersingthe article in the antibacterial agent composition or the antiviralagent composition, in each case a substance having an oxygen-containingfunctional group, such as an —OH or —O— group, on its surface is used.As described above, since the antibacterial agent composition or theantiviral agent composition contain the silicon-containing compoundhaving an ethoxy group represented by the general formula (1), such anethoxy group reacts with an oxygen-containing functional group on thesurface of the treated article to release ethanol, while being linkedtogether by covalent bonding via oxygen. As a result, an antibacterialor antiviral active site of the silicon-containing compound is firmlyfixed to the surface of the treated article, and a strong antibacterialor antiviral ability and an excellent persistence are imparted to thesurface of the treated article.

The treated article may be any substance that has an oxygen-containingfunctional group, such as —OH or —O— group on its surface, including,but not limited to, ranging from minute articles, such as dentalmaterials, to other articles, such as textile products including towelsor clothes, and further to large articles. In addition, to apply such anoxygen-containing functional group to a surface of the article, surfacetreatment may be performed in advance to apply the oxygen-containingfunctional group to the surface of the treated article prior toapplication of the antibacterial or antiviral agent composition. Suchsurface treatment is preferably, for example, ozone water treatment, andmore specifically, includes treatments for immersing in ozone water,spraying ozone water or applying ozone water. Since such ozone watertreatment specifically involves a simple process including immersion,spraying, application by means of ozone water, this allows for flexiblesupport of any articles, for example, from minute articles to largearticles, and easy treatment and incorporation in a production line.Thus the antibacterial or antiviral agent composition can be fixed to asurface of an article more firmly.

The above-described process with ozone water may be performed, withoutlimitation, for example, by using ozone water with appropriatelyadjusted concentration, while changing the treatment times depending onthe concentration of that ozone water as necessarily. Specifically, forexample, if the concentration of ozone is from 0.4 to 0.6 ppm, thenimmersion treatment only may be performed for about 5 minutes; and fornormal ozone water in a concentration of several ppm, only simple sprayand natural dry treatment has to be performed to provide the articlewith a more sufficient antibacterial ability or antiviral ability andthe persistence.

EXAMPLE

While examples of the present invention will be presented specifically,the present invention is not limited to the disclosed examples.Meanwhile, the following abbreviations are used in the examples:

-   -   EtAC: octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride    -   Si-QAC: octadecyldimethyl(3-trimethoxysilylpropyl)ammonium        chloride    -   CPB: cetylpyridinium bromide    -   Aromox®: lauryl dimethyl amine oxide (manufactured by Lion        Corporation)    -   LAD: lauroyl amidepropyl dimethyl amine oxide (manufactured by        Kawaken Fine Chemicals Co., Ltd.)    -   HD: hexadecyltrimethylammonium chloride    -   CPC: cetylpyridinium chloride    -   PO: polyoxyethylene sorbitan monolaurate    -   CDE: coco fatty acid diethanolamide    -   ethanol for disinfection (70%): (alcohol for disinfection of as        defined by the Japanese Pharmacopoeia)

Synthesis Example 1 Synthesis ofDimethyloctadecyl[3-(triethoxysilyl)propyl]Ammonium Chloride EthanolSolution

Firstly, 41.5 g (0.17 moL) of triethoxysilylpropyl chloride (Tokyo KaseiKogyo Co., Ltd.), 44.6 g (0.150 moL) of N,N-dimethyl octadecylamine(Tokyo Kasei Kogyo Co., Ltd.) and 40.5 g of ethanol are fed into anitrogen-purged pressurized reactor and heated to 135° C. After thereaction for 20 hours, 121.4 g ofdimethyloctadecyl[3-(triethoxysilyl)propyl]ammonium chloride (EtAC) inethanol solution is obtained.

Content: 63.8% Net Amount: 77.5 g Yield: 95.9%

It should be noted that the identification ofdimethyloctadecyl[3-(triethoxysilyl)propyl]ammonium chloride isperformed by MS. The measurement conditions and spectral data are asfollows:

1) Measurement Conditions:

-   -   Mass range: 22.0458-711.451 m/z    -   Ionization method: FAB (fast atom bombardment)    -   Mode: positive

2) Spectral Data: m/z=530

Safety Test Examples 1-3

To ascertain the safety of the composition of the present inventioncontaining octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, amutagenicity test, an acute oral toxicity test with female mice and aprimary skin irritation test with rabbits are conducted.

Test Example 1 Mutagenicity Test

As a specimen, the 60 wt. % EtAC ethanol solution obtained in SynthesisExample 1 (a light yellow transparent liquid) is used, and for thepurpose of testing mutagenicity of such a specimen, a reverse mutationassay is performed with four Escherichia coli WP2uvrA and Salmonellatyphimurium TA series strains (TA100, TA1535, TA98 and TA1537) inaccordance with Ministry of Labour Notification No. 77 (Sep. 1, 1988).In this test, a bacterial liquid for assay is obtained by inoculating adefrosted bacteria-dispensed cryopreservation liquid into a baffleconical flask, into which 15 mL of nutrient broth medium [OXOID,Nutrient broth No. 2] is dispensed, which is then subjected to gyratoryculture at 37° C. for 10 hours. The specimen is sampled and addedinjection water, and then a test stock solution is prepared and dilutedas appropriate with injection water, after which a test liquid isprepared. As positive control substances,2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide, sodium azide, 9-Aminoacridinehydrochloride and 2-Aminoanthracene are used. The injection water isconsidered as negative control, and the test is then performed in a doseof 0.610-1250 μg/plate.

As a result, in a sterility test, neither the test stock solution northe S9mix exhibit a twofold or greater increase in the number of reversemutant colonies as compared with the negative control value. In thiscase, no growth of bacteria is observed. In contrast,2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide, sodium azide and9-Aminoacridine hydrochloride used as positive control exhibit aremarkable increase in the number of reverse mutant colonies as comparedwith negative control. In addition, 2-Aminoanthracene induces an obviousreverse mutation in the presence of S9mix. From this, the mutagenicityof the specimen under the conditions of Test Example 1 is determined asnegative.

Test Example 2 Acute Oral Toxicity Test with Female Mice

The 60 wt. % EtAC ethanol solution obtained in Synthesis Example 1 isdiluted with an injection solution to prepare 400, 300, 200 and 100mg/ml of test liquids. This solution is orally administered to mice witha dosage of 8,000, 6,000, 4000 and 2,000 mg/kg, whereas control group isorally administered single dose of water for injection to female mice,which are then observed for 14 days.

As a result, for all samples in the groups administered 8,000, 6,000,4,000 mg/kg and 2 samples in the group administered 2,000 mg/kg, adecrease in locomotor activity is observed 5 minutes after theadministration, but they recover within 4 hours after the administrationand no abnormality is recognized thereafter (zero dead sample under allconditions). This shows that the LD50 value obtained by the single oraladministration in the specimen mice is 8,000 mg/kg or more.

Test Example 3 Primary Skin Irritation Test with Rabbits

The EtAC ethanol solution obtained in Synthesis Example 1 is dilutedwith ethanol for disinfection (80% ethanol) to prepare a 80% ethanolsolution of 3 wt. % EtAC, which is then sprayed on a 100% cotton towel,left at room temperature for 3 minutes, then washed under running waterand dried, by which an EtAC-treated towel is fabricated. Such a treatedtowel is considered as a specimen, and a primary skin irritation testwith rabbits is conducted in accordance with OECD Guidelines for theTesting of Chemicals 404 (2002). The specimen, which is cut to about 2cm by 3 cm, is wetted with about 0.5 mL of injection water, which isthen applied to three rabbits at each single site of a wound skin and anintact skin of each rabbit for 24 hours.

As a result, a very slight erythema (one mark) is seen in the wound skinof one sample after 1 hour of the removal, but it disappears within 24hours and no irritation response is observed afterwards. In theremaining application sites, no irritation response is observedthroughout the observation period. Primary irritation index (P.I.I.),which is required in accordance with Federal Register (1972), is 0.1,and the specimen is assessed as in the category of “Non-irritant” in theprimary skin irritation test with rabbits.

Example 1 Stability Test in 3 wt. % EtAC Aqueous Solution

The 60 wt. % EtAC ethanol solution obtained in Synthesis Example 1 ismixed with water and various surfactants and the stability is comparedbetween them. The surfactants used are CPB, Aromox and LAD as amphotericsurfactants, HD and CPC as cationic surfactants, and PO and CDE asnon-ionic surfactants. The final concentration of EtAC is adjusted to 3wt. %. The final concentration of each surfactant is adjusted such thatthe non-ionic surfactant and the amphoteric surfactant are 1 wt. % andthe cationic surfactant 0.1 wt. %. The resultant solutions are observedfor the presence of precipitation after form 5 days to 2 weeks. Theresults are shown in Tables 1-2.

TABLE 1 Surfactant after 5 days after 2 weeks onward 1 Aromox clearclear 2 LAD clear clear 3 Aromox + CPC clear clear 4 LAD + CPC clearclear 5 none cloudy cloudy 6 PO clear cloudy 7 CDE clear cloudy

TABLE 2 Surfactant after 5 days 8 CPC clear

The solutions using amphoteric surfactant or amphotericsurfactant+cationic surfactant do not form a precipitate even after 2weeks, and are thus found to be stable (Table 1; Entry 1-4).

In contrast, for comparison purposes, a surfactant-free solution, anon-ionic surfactant and a cationic surfactant are also subjected to asimilar test, in which case a precipitate is formed at the time point ofpassing 5 days to 2 weeks, respectively (Table 1; Entry 5-7).

Example 2 Stability Test in 3 wt. % EtAC Ethanol Solution forDisinfection

The 60 wt. % EtAC ethanol solution obtained in Synthesis Example 1 ismixed with cationic surfactants, which are then diluted twenty-fold withethanol for disinfection and prepared such that the final concentrationof EtAC is 3 wt. % and the final concentration of the surfactant 1 wt.%, respectively. HD and CPC are used as the cationic surfactants. Theresultant solutions are verified for the presence of precipitation. Theresults are shown in Table 3.

TABLE 3 Surfactant 1 none cloudy 2 HD clear 3 CPC clear

The solutions with addition of HD and CPC do not form a precipitate andare thus found to be stable (Table 3; Entry 2 and 3).

In contrast, for comparison purposes, a surfactant-free solution is alsosubjected to a similar test, in which case precipitate is formed severalhours after mixing (Table 3; Entry 1).

Example 3 Test 1 for Comparing Antibacterial Abilities Between EtAC andSi-QAC

A 60 wt. % Si-QAC methanol solution or the 60 wt. % EtAC ethanolsolution obtained in Synthesis Example 1 is mixed with a surfactant,which is then diluted twenty-fold with water or ethanol fordisinfection, and prepared such that the final concentrations of EtAC orSi-QAC and the surfactant are:

3% SiQAC+1% PO, 3% EtAC+1% LAD, 3% EtAC+1% LAD+0.1% CPC (three specimensof aqueous solution); and

3% EtAC+0.1% HD, 3% EtAC+0.1% CPC (two specimens of ethanol fordisinfection solution).

Cover glasses for counting chamber are immersed in MQ water (control)and the five resultant solution specimens for 30 minutes, respectively,which are then removed and left for an hour before washing with water toremove excess solution. Then, 50 μL of bacteria suspension of 10⁶ CFU/mLCandida albicans GDH18 is inoculated, left at room temperature for 2hours, then added 3 mL of Sabouraud medium and cultured at 37° C. for 22hours.

Absorbance is used for calculation of the number of bacteria(wavelength: 600 nm, measurement device: BioPhotometer). The absorbanceof 0.3 is equivalent to 10⁷ CFU/mL.

The results are reported in FIG. 1. As illustrated in FIG. 1, bacterialgrowth is not observed at all on the glass surface which is treated with3% EtAC+1% LAD (LADEtAC), 3% EtAC+1% LAD+0.1% CPC (LAD+CPCEtAC), 3%EtAC+ethanol for disinfection solution of 0.1% HD (HDEtAC eth) and 3%EtAC+ethanol for disinfection solution of 0.1% CPC(CPCEtAC eth), whereasSi-QAC (POSi-QAC) involves a bacterial proliferation of about 2.6×10⁷CFU/mL, suggesting that a very strong antibacterial ability is obtainedeven compared with conventional silicon-containing compounds of methoxybody.

Example 4 Comparison Test 2 for Antibacterial Abilities Between EtAC andSi-QAC

A 60 wt. % Si-QAC methanol solution or the 60 wt. % EtAC ethanolsolution obtained in Synthesis Example 1 is mixed with a surfactant andwater, which is then prepared such that the final concentrations of EtACor Si-QAC and the surfactant are:

3% SiQAC+1% PO, 3% SiQAC+1% PO+HD, 3% SiQAC+1% LAD, 3% EtAC+1% LAD, 3%EtAC+1% LAD+0.1% CPC (aqueous solutions).

Cover glasses for counting chamber are immersed in the resultantsolutions for 45 minutes, removed and washed with water to remove excesssolution, then left and dried for 1 hour, which is used in anexperiment. Subsequently, 50 μL of bacteria suspension of 10⁶ CFU/mL C.albicans GDH18 is inoculated, left at room temperature for 2 hours, thenadded 3 mL of Sabouraud medium is added and cultured at 37° C. for 24,48 and 90 hours.

For the number of bacteria, a Candida yellow medium is used for simplecalculation. The color of the medium remains red if bacteria do not growon the medium (circle, “∘”); it changes to orange in the event ofgrowing bacteria being 5×10⁶ CFU/mL (triangle, “Δ”); or it changes toyellow when 1×10⁸ CFU/mL (ex, “X”).

The results are shown in Table 4. For all of the glasses treated underrespective conditions, the medium assumes red color for 24 hours (∘).From this, it is considered that growth inhibition is possible up to 24hours after inoculation by antibacterial processing in any of thesolutions. After 48 hours, growth inhibition is only observed in eachsolution of 3% EtAC+1% LAD and 3% EtAC+1% LAD+0.1% CPC using EtAC (∘).Furthermore, after 90 hours, growth inhibition is only observed in theglass treated with 3% EtAC+1% LAD+0.1% CPC (∘).

TABLE 4 24 hr 48 hr 90 hr 1 3% Si—QAC + 1% PO + water ◯ Δ X 2 3%Si—QAC + 1% PO + HD + water ◯ Δ X 3 3% Si—QAC + 1% LAD + water ◯ Δ X 43% EtAC + 1% LAD + water ◯ ◯ X 5 3% EtAC + 1% LAD + 0.1% CPC + water ◯ ◯◯

Example 5 Test 1 for Antibacterial Ability in 3 wt. % EtAC AqueousSolution

The 60 wt. % EtAC ethanol solution obtained in Synthesis Example 1 ismixed with amphoteric surfactants and water, which are then preparedsuch that the final concentration of EtAC is 3% and the finalconcentration of the amphoteric surfactants 1%, respectively. CPB,Aromox and LAD are used as the amphoteric surfactants.

The resultant solutions are placed into a glass bottle, immersed for 20minutes, removed and washed with water to remove excess solution, thenleft and dried for 3 hours, which is used in an experiment.Subsequently, 50 μL of bacterial suspension of 10⁶ CFU/mL C. albicansGDH18 is inoculated, left at room temperature for 12 hours, then added 3mL of Sabouraud medium and cultured at 37° C. for 24 and 100 hours.

For the number of bacteria, a Candida yellow medium is used for simplecalculation. The color of the medium remains red when bacteria do notgrow on the medium (circle, “∘”); it changes to orange in the event ofgrowing bacteria being 5×10⁶ CFU/mL (triangle, “Δ”); or it changes toyellow when 1×10⁸ CFU/mL (ex, “X”).

The results are shown in Table 5. For all of the glasses treated underrespective conditions, the medium assumes red color for 24 hours (∘).From this, it is considered that growth inhibition is possible up to 24hours after inoculation by antibacterial processing in any of thesolutions.

After 100 hours, as illustrated in Table 5, growth inhibition isobserved in each solution added Aromox or LAD using EtAC (∘).

TABLE 5 24 hr 100 hr 1 3% EtAC + 1% Aromox + water ◯ ◯ 2 3% EtAC + 1%LAD + water ◯ ◯

Example 6 Test 2 for Antibacterial Ability in 3 wt. % EtAC AqueousSolution

The 60 wt. % EtAC ethanol solution obtained in the Synthesis Example 1is mixed with water and various surfactants and the stability iscompared among them. The surfactants used are CPB, Aromox and LAD asamphoteric surfactants and PO as a non-ionic surfactant. The finalconcentration of EtAC is adjusted to 3 wt. % and the final concentrationof each surfactant to 1 wt. %.

The resultant solutions are placed into a glass bottle, immersed for 20minutes, removed and washed with water to remove excess solution, thenleft and dried for 3 hours, which is used in an experiment.Subsequently, 50 μL of bacteria suspension of 10⁶ CFU/mL C. albicansGDH18 (bacterial count: about 10,000) is inoculated and cultured at 37°C. for 18 hours.

For the number of bacteria, a Candida yellow medium is used for simplecalculation. The results are shown in FIG. 2. The vertical axis of FIG.2 represents the number of bacteria that are detected after beingcultured for 18 hours (logarithm value). That is, if the vertical axisis 8, the number of bacteria present is 100,000,000; if the verticalaxis is 6, the number of bacteria is 1,000,000. Any of these surfactantsyield values lower than 4 of the number of inoculated bacteria (10,000bacteria). It can be seen, however, that Aromox, in particular, yields 2in logarithm value, namely around 100 bacteria, which may provide veryhigh antibacterial abilities. This suggests a possibility thatparticularly EtAC and Aromox produce intermediates and thereby enhancethe reactivity. Accordingly, upon analysis of the product in theabove-described solution with FT-IR, production of intermediates isidentified.

Example 7 Test for Antibacterialization of Hydroxyapatite

The 60 wt. % EtAC ethanol solution obtained in Synthesis Example 1 ismixed with Aromox and water, which is then prepared such that the finalconcentration of EtAC is 3% and Aromox 1%.

Sintered hydroxyapatite (Pentax APP-100) of 1 cm square (2 mm thick) isimmersed in the resultant aqueous solutions for 5, 10, 20, 30 minutes,then removed and washed with water to remove excess solution, and leftand dried for 1 hour, which is then used in an experiment.

Then, 20 μL of bacteria suspension of 10⁶ CFU/mL C. albicans GDH18 isinoculated, left at room temperature for 4 hours, then added 2 mL ofSabouraud medium and cultured at 37° C. for 24, 32 and 44 hours.

For the number of bacteria, a Candida yellow medium is used for simplecalculation. The color of the medium remains red when bacteria do notgrow on the medium (circle, “∘”); it changes to orange in the event ofgrowing bacteria being 5×10⁶ CFU/mL (triangle, “Δ”); or it changes toyellow when 1×10⁸ CFU/mL (ex, “X”).

The results are shown in Table 6. For all of the hydroxyapatite treatedunder respective conditions, the medium assumes red color for 24 hours(∘). From this, it is considered that growth inhibition is possible upto 24 hours after inoculation by antibacterial processing in any of thesolutions. The bacteria growth of untreated hydroxyapatite (control) isabout 5×10⁶ CFU/mL (Δ).

For all of the hydroxyapatite treated under respective conditions, themedium assumes red color for 32 hours (∘). From this, it is consideredthat growth inhibition is possible up to 32 hours after inoculation byantibacterial processing in any of the solutions. For the untreatedhydroxyapatite (control), the medium assumes yellow color (X) andbacteria growth to be about 1×10⁸ CFU/mL.

After 44 hours, bacterial growth is observed (Δ) for the hydroxyapatitesubjected to immersion for five minutes, while no growth being observed(∘) for others subjected to immersion for 10, 20, 30 minutes.

TABLE 6 Immersion Time (min) 24 hr 32 hr 44 hr 1 untreated Δ X X 2 5 ◯ ◯Δ 3 10 ◯ ◯ ◯ 4 20 ◯ ◯ ◯ 5 30 ◯ ◯ ◯

Example 8 Virus Inactivation Test

A test is performed to determine whether the detergent composition andthe composition for disinfection, cleaning, mouth rinsing, sterilizationand antibacterialization of the present invention have an ability toinactivate viruses. The viruses used are influenza virus and felinecalicivirus (which belongs to the same genus as the human norovirus andis known to grow in CRFK cells of feline kidney cells, and which can beused as an alternative experimental system of human norovirus).Measurement of virus titer is performed by the 50% Tissue CultureInfectious Dose (TCID₅₀) method.

As a test solution, an 80% ethanol solution of 3 wt. % EtAC is prepared.A 10 cm² cell culture dish is used to culture canine kidney cells in thecase of influenza virus and CRFK cells in the case of feline calicivirusto 70-100% confluent. Then, 100 μL of 100TCID₅₀ influenza virus orfeline calicivirus solution with 100 μL of test solution are added andplaced in contact with 0.8 mL of 5% FCS-DMEM for 1 hour (as a result,viruses are diluted ten-fold to 10TCID₅₀). Subsequently, 100 μL of 5%FCS-DMEM comprising virus is inoculated into 0.9 mL of cell cultureliquid (5% FCS-DMEM), which is then cultured (as a result, viruses arediluted another 10-fold to 1TCID₅₀). After 4-5 and 7-8 days, DMEMsupplemented with 50 μL of 10% FCS is gently added to each well,respectively. After 11-13 days, a termination point of cytopathy isdetermined by a microscope. For each test solution and an untreatedcontrol using distilled water instead of each test solution, 50% tissueinfectious rate (TCID₅₀) is calculated by the Reed-Muench method. As aresult, 0.8-1.2 TCID₅₀ is obtained for the control (untreated), and theviral infection to the used culture cells is observed. However, whentreated with a solution containing EtAC, infection by any of viruses isnot observed. From this, it is considered that the viruses areinactivated upon inoculation.

Example 9 Test for Virus Infection Inactivating Ability AgainstInfluenza Virus

As influenza viruses, orthomyxoviridae influenza virus AA/swan/Shimane/499/83(H5N3) which is avian asymptomatic (an attenuatedstrain) and a atypical (swine) influenza virus (type H1N1) are used.They are purified by a sucrose density-gradient centrifugation and usedas a virus liquid dialyzed against PBS. MDCK(+) cell which is a cellline of canine kidney cells is also used.

The above-described virus solution and the EtAC ethanol solutionobtained in Synthesis Example 1 are mixed at a ratio of 1:9 (10 μL+90μL), which is then reacted at room temperature for 3 minutes. From theprocessed virus liquid, 10-steps serial dilutions (including 0.6% EtAC,0.2% EtAC, 0.06% EtAC, 0.02% EtAC, 0.006% EtAC, 0.002% EtAC, 0.0006%EtAC, 0.0002% EtAC, 6×10⁻⁵% EtAC, 0% EtAC) are prepared with DMEM,inoculated into a monolayer cultured cell in a 96-well plate (50μL/well), and subjected to a virus adsorption for 1 hour. The virusinoculated liquid is then removed by suction and DMEM, 20 μg/ml trypsin(100 μL/well) are added afterwards. This is fixed and stained uponspread of CPE after 5 days. Then, 50% tissue culture infectious rate (inTCID50) is calculated by the Behrens-Kaerber method to measure avirus-infectivity titer.

The results are reported in FIGS. 3 and 4. As illustrated in FIG. 3, itcan be seen that when an EtAC ethanol solvent is diluted with DMEM, itis still effective if diluted to a residual infectivity titer of 0.002%(20 ppm). It should be noted that the above-described virus is an avianinfluenza attenuated strain, and the above-described virus liquid is aliquid that is purified by a sucrose density-gradient centrifugation anddialyzed against PBS, which results in less incorporation of impurities.In addition, as is the case with the results obtained for the avianinfluenza virus, highly significant effects are found for the atypicalinfluenza virus (type H1N1) (see FIG. 4). It is assumed that theseresults are also common to the human type (H1N1, H3N2), type A influenzavirus having the same physical properties as the avian influenza virus.

Example 10 Test for Anti-influenza Virus Action of EtAC-Treated Toweland EtAC-Treated Glass Vial

The viruses (virus liquids) and cells used are the same as those used inExample 9.

The EtAC ethanol solution obtained in Synthesis Example 1 is dilutedwith ethanol for disinfection (80% ethanol) to prepare 80% ethanolsolutions of 3 wt. % EtAC, 0.3 wt. % EtAC and 0.06 wt. % EtAC, which isthen sprayed on a 100% cotton towel, left at room temperature for 3minutes, then washed under running water and dried, by which anEtAC-treated towel is fabricated.

Then, about 17 mg of the resultant towel is weighed and placed into eachwell of a 24-well plate, which 50 μL of virus liquid is added dropwiseand perfused. After the incubation at room temperature for 30 minutes,300 μL DMEM (Dulbecco's modified Eagle's MEM) is added and viruses arecollected with pipetting.

Then, the above 80 wt. % EtAC/ethanol solutions are adjusted to theconcentrations of 0.3%, 0.15%, 0.1%, 0.75%, 0.06%, 0.03%, 0.01%, whilethe inner surface of the vial bottle is processed at room temperaturefor 10 minutes and then washed with ethanol four times and driedafterwards, by which an EtAC-treated glass vial is fabricated.

Then, the virus liquid (50 μL, or 50 μL virus liquid+250 μL DMEM) isplaced into the resultant vial under shaking while incubating with ashaker for 30 minutes.

From the processed virus liquid, as is the case with Example 9, 10-stepsserial dilutions are prepared with DMEM, inoculated into a monolayercultured cell in a 96-well plate (50 μL/well), and subjected to a virusadsorption for 1 hour.

The virus inoculated liquid is then removed by aspiration, then DMEM and20 μg/mL trypsin (100 μL/well) are added afterwards. This is fixed andstained upon spread of CPE after 5 days. Then, 50% tissue cultureinfectious dose (in TCID50) is calculated by the Behrens-Kaerber methodto measure a virus-infectivity titer.

The results are shown in FIG. 5. As illustrated in FIG. 5, it is foundthat both the EtAC-treated towel and EtAC-treated glass vial exhibit avery strong inactivation ability when treated at a concentration of0.06% EtAC (80% ethanol solvent) or more.

1. An antibacterial agent composition comprising silicon-containingcompound obtained from general formula (a):X—(CH₂)₃—Si—(OCH₂CH₃)₃  (a), wherein X represents halogen ion or organiccarbonyloxy ion (organic carboxylate ion), which representstriethoxysilyl compound reacted in ethanol solvent to obtain by generalformula (1) in an amount of 0.006-24 wt. % and further comprisingethanol and water:

wherein R¹ represents an alkyl group having from 12 to 24 carbon atoms;R² and R³ represent lower alkyl groups, respectively, having from 1 to 6carbon atoms, which carbon atoms may be the same or different from eachother; and X represents a halogen ion or an organic carbonyloxy ion(organic carboxylate ion).
 2. The antibacterial agent compositionaccording to claim 1, wherein the silicon-containing compoundrepresented by the general formula (1) is octadecyldimethyl(3-triethoxysilylpropyl) ammonium chloride.
 3. The antibacterial agentcomposition according to claim 1 or 2 further comprising a amphotericsurfactant and/or a cationic surfactant.
 4. An antibacterializing methodcomprising antibacterializing a surface of a article with theantibacterial agent composition according to any one of claims 1-3.
 5. Acleaning/mouth rinsing method comprising cleaning/mouth rinsing with theantibacterial agent composition according to any one of claims 1-3. 6.An antiviral agent composition comprising a silicon-containing compoundrepresented by general formula (1):

where R1 represents an alkyl group having 12-24 carbon atoms; R2 and R3are lower alkyl groups having 1-6 carbon atoms that may be the same ordifferent; and X is a halogen ion or an organic carbonyloxy ion (organiccarboxylate ion).
 7. The antiviral agent composition according to claim6, wherein the silicon-containing compound represented by the generalformula (1) is octadecyldimethyl(3-triethoxysilylpropyl)ammoniumchloride.
 8. The antiviral agent composition according to claim 6 or 7further comprising ethanol.
 9. The antiviral agent composition accordingto any one of claims 6-8 further comprising water.
 10. The antiviralagent composition according to any one of claims 6-9 further comprisinga amphoteric surfactant and/or a cationic surfactant.
 11. The antiviralagent composition according to any one of claims 6-10 comprising anability to inactivate at least one type of virus selected from the groupconsisting of: type A influenza virus (human, avian, swine (atypical)),type B influenza virus, parainfluenza virus and norovirus.
 12. A articleof manufacture for fixing an antibacterial agent made by a processcomprising: by means of a substance having an oxygen-containingfunctional group on its surface, applying or spraying the antibacterialagent composition according to any one of claims 1-3 onto the surface ofa article, or immersing the article in the antibacterial agentcomposition according to any one of claims 1-3.
 13. A method for fixingan antibacterial agent, comprising: by means of a substance having anoxygen-containing functional group on its surface, applying or sprayingthe antibacterial agent composition according to any one of claims 1-3onto the surface of the article, or immersing the article in theantibacterial agent composition according to any one of claims 1-3. 14.A method for fixing an antiviral agent, comprising: by means of asubstance having an oxygen-containing functional group on its surface,applying or spraying the antiviral agent composition according to anyone of claims 6-11 onto the surface of the article, or immersing thearticle in the antiviral agent composition according to any one ofclaims 6-11.
 15. (canceled)